Summary
Call Text (Last updated on 17 May 2024)Guidelines for applicantsPre-proposal application form (in MSWord)Full proposal application form (in MSWord)
Documents
Funded projects
Projects funded under this call.
ACCELERATE
Functional precision medicine platform for the treatment of pancreatic cancer
View project
BePrepared
Building an ex vivo complex tumour microenvironment platform for development of combination therapies and drug resistance studies in head neck cancer
View project
DOPPLER-LC
Development Of Patient-derived organoid PLatform for Evading Resistances in Lung Cancer
View project
GLIO-COMBO
Targeting tumor heterogeneity in pediatric high-grade gliomas
View project
HAVOC
Human avatar on chip for advancing personalized cancer therapies by integrating vascular and immune components in a Tumor-on-Chip model
View project
ioAVATAR
Immune oncology Drug Discovery & Decision - Advanced ex Vivo Approach To Accelerate Response prediction for combined therapies in ovarian cancer
View project
LUNGOIDS
Subtype-specific Lung Cancer Organoids based on artificial ECM for Precision Oncology: Closing the Gap Between Preclinical Models and Patient Care
View project
MELANOLOCK
Tackling resistance to immunotherapy in advanced melanomas through the inhibition of oncomiRs by Locked Nucleic Acids
View project
METRICs
Metabolism/Metagenomics-based strategies for sensitization to Radio- and Immuno- therapy Combinations.
View project
PREDICT-BC
Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary Cancer
View project
SARAH
Search for combinational therapy to target clonal haematopoiesis in solid malignancies
View project
SeqPerGlio
Intraoperative tumour sequencing for personalized loco-regional drug combination therapy against glioblastoma recurrences
View project
TITAN
Novel Cancer Therapy: Inducing Double-strand DNA Breaks to Foster Tumor Cell Death, Antigenicity and Immunotherapy Response in New Personalized Models
View project
TOSCANINI
TAD disruption and aberrant expression as leukemia metabolic vulnerabilities for novel combination therapy tests in a drug screening platform
View project
XPANTHER